Can Mesa Labs (NASDAQ:MLAB) Sustain Operating Income Growth After Its First Full-Year Guidance?

Sonal Goyal

10 November 2026 06:56 PM AEDT

Can Mesa Labs (NASDAQ:MLAB) Sustain Operating Income Growth After Its First Full-Year Guidance?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue rose 2.6% to $62.3 million in the fiscal second quarter of 2027.
Sterilization and Disinfection Control Revenue increased 14.6% to $25.3 million.
Operating income climbed 77.6% to $8.4 million, and Net Income rose 75.3%.
The company issued its first full-year guidance.

Mesa Laboratories, Inc. (NASDAQ:MLAB) reported revenue of $62.3 million for its fiscal second quarter of 2027, ended September 30, 2026, an increase of 2.6% from the prior-year period. The Lakewood, Colorado-based company designs and manufactures quality control solutions and life sciences tools.

Revenue Composition

Organic revenue, which excludes acquisitions and currency effects, grew 2.6% on a non-GAAP basis, while constant-currency organic growth was 3.1%. Excluding the Clinical Genomics business, revenue increased 5.2% to $52.2 million, or 5.8% in constant currency.

For the first six months of the fiscal year, revenue reached $102.0 million, an increase of 3.2% over the prior-year period.

Sterilization and Disinfection Control

The Sterilization and Disinfection Control division was the fastest-growing area of the Business in the quarter, with revenue up 14.6% to $25.3 million. Over the last twelve months, the division's revenue rose 8.5% to $103.9 million, which the company described as the highest twelve-month total in the division's history.

The company reported Operating Income of $8.4 million, up 77.6%, and net income increased 75.3%.

First Full-Year Guidance

The company issued its first full-year guidance with the quarterly results.

Mesa Labs reports revenue in several divisions that serve laboratories, hospitals and manufacturers. Sterilization and disinfection control instruments are used to validate that processes such as steam and gas sterilization are working correctly, and Demand for that work is tied to regulated quality control activity. Clinical genomics is a smaller business whose revenue behaves differently and is reported separately in the company's analysis.

Final Word

Mesa Labs' fiscal second quarter combines modest revenue growth with a much larger rise in operating income, and the Sterilization and Disinfection Control division has led the expansion.

FAQs

Q: What was Mesa Labs' fiscal second-quarter 2027 revenue?

A: Revenue was $62.3 million, an increase of 2.6% from the prior-year period.

Q: Which division grew fastest?

A: Sterilization and Disinfection Control revenue rose 14.6% to $25.3 million in the quarter.

Q: How much did operating income change?

A: Operating income increased 77.6% to $8.4 million.

Q: Did Mesa Labs issue guidance?

A: Yes. The company issued full-year guidance for the first time with its fiscal second-quarter results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.